𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chemoradiation in advanced nonsmall cell lung cancer

✍ Scribed by Julianna Pisch; Anthony M. Berson; Stephen Malamud; Edward J. Beattie; James Harvey; Bhadrasain Vikram

Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
633 KB
Volume
33
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Implications of key trials in advanced n
Implications of key trials in advanced nonsmall cell lung cancer
✍ Philip D. Bonomi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

## Abstract Many different targeted therapies with varying mechanisms of action have been added to standard first‐line chemotherapy doublets in an effort to improve survival of patients with advanced nonsmall cell lung cancer (NSCLC). Only 2 targeted therapies—bevacizumab and cetuximab—have been as

Second-line treatments after first-line
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
✍ Jenn-Yu Wu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 236 KB

## Abstract Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second‐line regimens could lead to better outcomes. To study the influence of different second‐line antitumor regimens on the outco

Positron emission tomography imaging in
Positron emission tomography imaging in nonsmall-cell lung cancer
✍ Jeremy J. Erasmus; Homer A. Macapinlac; Stephen G. Swisher 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 537 KB

## Abstract Positron emission tomography (PET) using 18F‐2‐deoxy‐D‐glucose, a D‐glucose analog labeled with fluorine‐18, complements conventional radiologic assessment in the evaluation of patients with nonsmall‐cell lung cancer (NSCLC). PET is being routinely used to improve the detection of nodal